A Phase 1/2 Open-Label, Multiple-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VT-464 in Patients With Castration-Resistant Prostate Cancer

Trial Profile

A Phase 1/2 Open-Label, Multiple-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VT-464 in Patients With Castration-Resistant Prostate Cancer

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 09 May 2017

At a glance

  • Drugs Seviteronel (Primary)
  • Indications Prostate cancer
  • Focus Adverse reactions; First in man
  • Sponsors Innocrin Pharmaceuticals; Viamet Pharmaceuticals
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 02 Sep 2016 Planned End Date changed from 1 Aug 2016 to 1 May 2017.
    • 02 Sep 2016 Planned primary completion date changed from 1 Jun 2016 to 1 May 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top